Comparative Pharmacology
Head-to-head clinical analysis: KEPPRA XR versus POTIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEPPRA XR versus POTIGA.
KEPPRA XR vs POTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.
None Documented
None Documented
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Category C
Category C
Antiepileptic
Antiepileptic